Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IIHDUAL: GLP-1 analogue assisted rapid weight loss in idiopathic intracranial hypertension
2024-517120-19-02Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in idiopathic intracranial hypertension (IIH) and obesity (2 arms), sponsored by Rigshospitalet. Primary endpoints: Change in lumbar opening pressure at 8 weeks and Change in body weight at 8 weeks. Started Dec 2024; status: completed.
02
Drugs
03
Conditions
idiopathic intracranial hypertension (IIH)obesity
Beyond the preview
Go deeper on 2024-517120-19-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517120-19-02.